125 related articles for article (PubMed ID: 38767878)
1. Federal Trade Commission Actions on Prescription Drugs, 2000-2022.
Daval CJR; Egilman AC; Sarpatwari A; Kesselheim AS
JAMA; 2024 Jun; 331(23):2029-2036. PubMed ID: 38767878
[TBL] [Abstract][Full Text] [Related]
2. Unsettling drug patent settlements: a framework for presumptive illegality.
Carrier MA
Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
[TBL] [Abstract][Full Text] [Related]
3. Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice?
Shah S; Silva MA; Malloy MJ
Nat Biotechnol; 2016 Jul; 34(7):716-9. PubMed ID: 27404880
[No Abstract] [Full Text] [Related]
4. The Role of Regulatory Agencies and Intellectual Property: Part II.
Noonan KE
Cold Spring Harb Perspect Med; 2015 Mar; 5(7):a020834. PubMed ID: 25775920
[TBL] [Abstract][Full Text] [Related]
5. Protecting competition and consumers: a conversation with Timothy J. Muris. Interview by William Sage.
Muris TJ
Health Aff (Millwood); 2003; 22(6):101-10. PubMed ID: 14649436
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
7. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
Leary TB
J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411
[TBL] [Abstract][Full Text] [Related]
8. An economic assessment of patent settlements in the pharmaceutical industry.
Dickey B; Orszag J; Tyson L
Ann Health Law; 2010; 19(2):367-400, 2 p preceding i. PubMed ID: 21443148
[TBL] [Abstract][Full Text] [Related]
9. The Federal Trade Commission and Consumer Protections for Mobile Health Apps.
Wagner JK
J Law Med Ethics; 2020 Mar; 48(1_suppl):103-114. PubMed ID: 32342745
[TBL] [Abstract][Full Text] [Related]
10. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
Yvon AM
Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
[No Abstract] [Full Text] [Related]
11. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
12. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
Brockmeier MS
Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
[No Abstract] [Full Text] [Related]
13. Medical Marketing in the United States, 1997-2016.
Schwartz LM; Woloshin S
JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
[TBL] [Abstract][Full Text] [Related]
14. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
Levy MS
Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis in health care antitrust.
Vita MG; Langenfeld J; Pautler P; Miller L
J Contemp Health Law Policy; 1991; 7():73-115. PubMed ID: 10111250
[TBL] [Abstract][Full Text] [Related]
16. Defending hospital mergers after the FTC's unorthodox challenge to the Evanston Northwestern--Highland Park transaction.
Campbell T
Ann Health Law; 2007; 16(2):213-39, table of content. PubMed ID: 17982822
[TBL] [Abstract][Full Text] [Related]
17. Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications?
Warchol JM
AMA J Ethics; 2019 Aug; 21(8):E661-667. PubMed ID: 31397661
[TBL] [Abstract][Full Text] [Related]
18. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
Ritter M; Tempesta J; Ragusa P
Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
[No Abstract] [Full Text] [Related]
19. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
20. Possible anticompetitive agreements between brand, generic companies to be studied.
Landis NT
Am J Health Syst Pharm; 2000 Dec; 57(23):2140, 2142. PubMed ID: 11127691
[No Abstract] [Full Text] [Related]
[Next] [New Search]
